Common Contracts

2,687,500 Shares CAPRICOR THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT

Underwriting Agreement • September 16th, 2016 • Capricor Therapeutics, Inc. • Pharmaceutical preparations • New York

• Contract Type
  Underwriting Agreement
• Filed
  September 16th, 2016
• Company
  Capricor Therapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 2,687,500 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 403,125 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”

] Shares HEMOSENSE, INC. Common Stock UNDERWRITING AGREEMENT

Underwriting Agreement • May 31st, 2005 • Hemosense Inc • Surgical & medical instruments & apparatus • New York

• Contract Type
  Underwriting Agreement
• Filed
  May 31st, 2005
• Company
  Hemosense Inc
• Industry
  Surgical & medical instruments & apparatus
• Jurisdiction
  New York

Hemosense, Inc., a Delaware corporation (the “Company”) proposes, subject to the terms and conditions contained herein, to sell to the several underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom Lazard Capital Markets LLC, W.R. Hambrecht + Co., LLC and Roth Capital Partners, LLC are acting as representatives (the “Representatives”), an aggregate of [ ] shares (the “Firm Shares”) of the Company’s common stock, $.001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional [ ] shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are herein, collectively, called the “Shares.”

7,000,000 Shares Seattle Genetics, Inc. Common Stock UNDERWRITING AGREEMENT

Underwriting Agreement • February 5th, 2004 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York

• Contract Type
  Underwriting Agreement
• Filed
  February 5th, 2004
• Company
  Seattle Genetics Inc /Wa
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

Seattle Genetics, Inc., a Delaware corporation (the “Company”) proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of 7,000,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 1,050,000 shares (the “Option Shares”) of Common Stock from the Company. The Firm Shares and the Option Shares are collectively called the “Shares.”